<DOC>
	<DOCNO>NCT00890448</DOCNO>
	<brief_summary>The purpose study examine genetic contribution mechanism lapaquistat acetate- induce hepatic abnormality .</brief_summary>
	<brief_title>Case Control Study Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure Lapaquistat Acetate</brief_title>
	<detailed_description>This modified case control study investigate association genotype phenotype subject experience alanine aminotransferase bilirubin derangement follow exposure lapaquistat acetate . The DNA profile subject experience significant biochemical hepatic derangement follow exposure lapaquistat acetate ( case ) compare population pre-genotyped untreated individual ( control ) public database . The DNA subject hepatic derangement lapaquistat acetate study , absence exposure lapaquistat acetate , store . If data subject expose lapaquistat acetate indicate genetic marker interest , store DNA non-exposed subject assay investigate signal . One 10 mL sample whole blood collect plastic K2EDTA tube , informed consent obtain . Each subject sign inform consent document prior undergoing study-related procedure . One 10 mL sample whole blood collect subject . Extracted DNA analyze use whole genome scan approach well candidate gene approach .</detailed_description>
	<criteria>Has experience alanine aminotransferase level great equal 5 time upper limit normal , concurrent elevation alanine aminotransferase great equal 3 time upper limit normal bilirubin great equal 2 time upper limit normal participate lapaquistat acetate clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Alanine Transaminase elevation</keyword>
	<keyword>Genetic Markers</keyword>
	<keyword>DNA Markers</keyword>
</DOC>